A cross-sectional study of 450 videos on TikTok, MicroBlog, and Today's Headline finds that only about 20 percent of breast ...
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after ...
Breast cancer remains the most commonly diagnosed cancer among South African women, with the latest National Cancer Registry figures showing that approximately one in every 28 women faces a lifetime ...
It began when she noticed the lump. Ashley Corthell discovered a small lump in her breast in March, but didn’t think anything ...
A tighter watch, ring, sleeve or shoe after cancer treatment may signal lymphedema. Learn the early signs, risk factors, ...
Considerations based on evidence as of October 2026Deciding whether to perform postoperative chemotherapy for breast ...
WOMEN have been urged to prioritise early breast cancer screening and seek medical attention promptly whenever they notice ...
US FDA approves Pfizer’s Tukysa in combo with trastuzumab & pertuzumab for maintenance treatment for HER2+ metastatic breast cancer: New York Friday, October 9, 2026, 12:00 Hrs ...
Medicare may not provide things entirely "for free," but some items and services are covered with no out-of-pocket costs under specific conditions.
Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with ...
TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results